-
A.
Rosenwald,
George
Wright,
K.
Leroy,
Xin-You
Yu,
P.
Gaulard,
R.
Gascoyne,
W.
Chan,
T.
Zhao,
C.
Haioun,
T.
Greiner,
D.
Weisenburger,
J.
Lynch,
J.
Vose,
J.
Armitage,
E.
Smeland,
S.
Kvaløy,
H.
Holte,
J.
Delabie,
E.
Campo,
E.
Montserrat,
A.
López-Guillermo,
G.
Ott,
H.
Muller-Hermelink,
J.
Connors,
R.
Braziel,
T.
Grogan,
T.
Grogan,
R.
Fisher,
R.
Fisher,
T.
Miller,
T.
Miller,
M.
LeBlanc,
M.
LeBlanc,
Michael
Chiorazzi,
Hong-Bo
Zhao,
Liming
Yang,
J.
Powell,
W.
Wilson,
E.
Jaffe,
R.
Simon,
R.
Klausner,
L.
Staudt
(2003)
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
The Journal of Experimental Medicine, 198
-
F.
Hodi,
M.
Mihm,
R.
Soiffer,
F.
Haluska,
M.
Butler,
M.
Seiden,
T.
Davis,
Rochele
Henry-Spires,
Suzanne
Macrae,
Ann
Willman,
R.
Padera,
M.
Jaklitsch,
S.
Shankar,
Teresa
Chen,
A.
Korman,
J.
Allison,
G.
Dranoff
(2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Proceedings of the National Academy of Sciences of the United States of America, 100
-
M.
Sant,
M.
López,
R.
Agresti,
M.
Pérez,
B.
Holleczek,
M.
Bielska-Lasota,
N.
Dimitrova,
K.
Innos,
A.
Katalinic,
H.
Langseth,
N.
Larranaga,
S.
Rossi,
S.
Siesling,
P.
Minicozzi
(2015)
Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study.
European journal of cancer, 51 15
-
W.
Huh,
D.
Dizon,
M.
Powell,
C.
Leath,
L.
Landrum,
E.
Tanner,
R.
Higgins,
S.
Ueda,
M.
McHale,
B.
Monk,
C.
Aghajanian
(2016)
ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study.
Journal of Clinical Oncology, 34
-
M.
Muller,
R.
Schouten,
C.
Gooijer,
P.
Baas
(2017)
Pembrolizumab for the treatment of non-small cell lung cancer
Expert Review of Anticancer Therapy, 17
-
L.
Chow,
R.
Mehra,
R.
Haddad,
A.
Mahipal,
J.
Weiss,
R.
Berger,
J.
Eder,
B.
Burtness,
M.
Tahara,
B.
Keam,
D.
Le,
K.
Muro,
R.
Geva,
H.
Chung,
Chia‐Chi
Lin,
M.
Ayers,
D.
Aurora-Garg,
J.
Lunceford,
Jonathan
Cheng,
T.
Seiwert
(2016)
Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Journal of Clinical Oncology, 34
-
S.
Stevanović,
Lindsey
Draper,
Michelle
Langhan,
T.
Campbell,
M.
Kwong,
J.
Wunderlich,
M.
Dudley,
J.
Yang,
R.
Sherry,
U.
Kammula,
N.
Restifo,
S.
Rosenberg,
C.
Hinrichs
(2015)
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 14
-
J.
Bernier
(2016)
Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing.
Critical reviews in oncology/hematology, 108
-
A.
Jemal,
F.
Bray,
Melissa
Center,
J.
Ferlay,
Elizabeth
Ward,
D.
Forman
(2011)
Global cancer statistics
CA: A Cancer Journal for Clinicians, 61
-
T.
Seiwert,
B.
Burtness,
R.
Mehra,
J.
Weiss,
R.
Berger,
J.
Eder,
K.
Heath,
T.
Mcclanahan,
J.
Lunceford,
C.
Gause,
Jonathan
Cheng,
L.
Chow
(2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
The Lancet. Oncology, 17 7
-
S.
Lheureux,
M.
Butler,
B.
Clarke,
M.
Cristea,
Lainie
Martin,
K.
Tonkin,
G.
Fleming,
A.
Tinker,
H.
Hirte,
D.
Tsoref,
H.
Mackay,
N.
Dhani,
P.
Ghatage,
N.
Pham,
V.
Motta,
Lisa
Wang,
K.
Karakasis,
S.
Udagani,
H.
Streicher,
A.
Oza
(2014)
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.
Journal of Clinical Oncology, 32
-
MonkBJ,
SillMW,
McMeekinDS
(2009)
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study
J Clin Oncol, 27
-
R.
Shrimali,
Zhiya
Yu,
M.
Theoret,
D.
Chinnasamy,
N.
Restifo,
S.
Rosenberg
(2010)
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Cancer research, 70 15
-
K.
Ohaegbulam,
Amer
Assal,
E.
Lázár-Molnár,
Yu
Yao,
X.
Zang
(2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Trends in molecular medicine, 21 1
-
T.
Nomi,
M.
Sho,
T.
Akahori,
K.
Hamada,
A.
Kubo,
H.
Kanehiro,
Shinji
Nakamura,
K.
Enomoto,
H.
Yagita,
M.
Azuma,
Y.
Nakajima
(2007)
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Clinical Cancer Research, 13
-
G.
Gibney,
L.
Weiner,
M.
Atkins
(2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
The Lancet. Oncology, 17 12
-
E.
Tivol,
F.
Borriello,
A.
Schweitzer,
William
Lynch,
J.
Bluestone,
Arlene
Sharpe
(1995)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Immunity, 3 5
-
J.
Brahmer,
K.
Reckamp,
P.
Baas,
L.
Crinò,
W.
Eberhardt,
E.
Poddubskaya,
S.
Antonia,
A.
Płużański,
E.
Vokes,
E.
Holgado,
D.
Waterhouse,
N.
Ready,
J.
Gainor,
O.
Frontera,
L.
Havel,
M.
Steins,
M.
Garassino,
J.
Aerts,
M.
Dómine,
L.
Paz-Ares,
M.
Reck,
C.
Baudelet,
C.
Harbison,
B.
Lestini,
D.
Spigel
(2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 2
-
T.
Schumacher,
R.
Schreiber
(2015)
Neoantigens in cancer immunotherapy
Science, 348
-
Lindsey
Torre,
F.
Bray,
R.
Siegel,
J.
Ferlay,
J.
Lortet-Tieulent,
A.
Jemal
(2015)
Global cancer statistics, 2012
CA: A Cancer Journal for Clinicians, 65
-
J.
Frenel,
C.
Tourneau,
B.
O'Neil,
P.
Ott,
S.
Piha-Paul,
C.
Gomez-Roca,
E.
Brummelen,
H.
Rugo,
S.
Thomas,
S.
Saraf,
Mei
Chen,
A.
Varga
(2016)
Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.
Journal of Clinical Oncology, 34
-
P.
Waterhouse,
J.
Penninger,
E.
Timms,
A.
Wakeham,
A.
Shahinian,
Kelvin
Lee,
C.
Thompson,
H.
Griesser,
T.
Mak
(1995)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Science, 270
-
P.
Basu,
A.
Mehta,
M.
Jain,
Sudeep
Gupta,
R.
Nagarkar,
Vijay
Kumar,
S.
Premkumar,
R.
Neve,
S.
John,
R.
Petit
(2014)
ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.
Journal of Clinical Oncology, 32
-
M.
Valsecchi
(2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
The New England journal of medicine, 373 13
-
J.
Thigpen
(2010)
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
Yearbook of Medicine, 2010
-
K.
Mahoney,
P.
Rennert,
G.
Freeman
(2015)
Combination cancer immunotherapy and new immunomodulatory targets
Nature Reviews Drug Discovery, 14
-
A.
Jemal,
F.
Bray,
Melissa
Center,
J.
Ferlay,
Elizabeth
Ward,
David
Forman
(2011)
Global Cancer Statistics
-
S.
Crafton,
R.
Salani
(2016)
Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
Clinical therapeutics, 38 3
-
K.
Petry,
Danicla
Scheffel,
Ulrike
Bode,
T.
Gabrysiak,
H.
Köchel,
E.
Kupsch,
M.
Glaubitz,
S.
Niesert,
H.
Kühnle,
I.
Schedel
(1994)
Cellular immunodeficiency enhances the progression of human papillomavirus‐associated cervical lesions
International Journal of Cancer, 57
-
E.
Garon,
N.
Rizvi,
R.
Hui,
N.
Leighl,
A.
Balmanoukian,
J.
Eder,
A.
Patnaik,
C.
Aggarwal,
M.
Gubens,
L.
Horn,
E.
Carcereny,
M.
Ahn,
E.
Felip,
Jong-Seok
Lee,
M.
Hellmann,
O.
Hamid,
J.
Goldman,
J.
Soria,
M.
Dolled-Filhart,
R.
Rutledge,
Jin
Zhang,
J.
Lunceford,
Reshma
Rangwala,
G.
Lubiniecki,
C.
Roach,
K.
Emancipator,
L.
Gandhi
(2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.
The New England journal of medicine, 372 21
-
F.
Hodi,
S.
O'Day,
D.
McDermott,
R.
Weber,
J.
Sosman,
J.
Haanen,
R.
Gonzalez,
C.
Robert,
D.
Schadendorf,
Jessica
Hassel,
W.
Akerley,
A.
Eertwegh,
J.
Lutzky,
P.
Lorigan,
J.
Vaubel,
G.
Linette,
D.
Hogg,
C.
Ottensmeier,
C.
Lebbé,
C.
Peschel,
I.
Quirt,
Joseph
Clark,
J.
Wolchok,
J.
Weber,
Jason
Tian,
M.
Yellin,
G.
Nichol,
A.
Hoos,
W.
Urba
(2010)
Improved survival with ipilimumab in patients with metastatic melanoma.
The New England journal of medicine, 363 8
-
S.
Boussios,
E.
Seraj,
G.
Zarkavelis,
D.
Petrakis,
Aristomenes
Kollas,
A.
Kafantari,
Abraam
Assi,
Konstantina
Tatsi,
N.
Pavlidis,
G.
Pentheroudakis
(2016)
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Critical reviews in oncology/hematology, 108
-
Yuichiro
Ohigashi,
M.
Sho,
Yukishige
Yamada,
Y.
Tsurui,
K.
Hamada,
N.
Ikeda,
T.
Mizuno,
R.
Yoriki,
H.
Kashizuka,
K.
Yane,
Fumihiko
Tsushima,
N.
Otsuki,
H.
Yagita,
M.
Azuma,
Y.
Nakajima
(2005)
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Clinical Cancer Research, 11
-
H.
Hausen
(2002)
Papillomaviruses and cancer: from basic studies to clinical application
Nature Reviews Cancer, 2
-
A.
Ribas,
C.
Robert,
F.
Hodi,
J.
Wolchok,
A.
Joshua,
W.
Hwu,
J.
Weber,
H.
Zarour,
R.
Kefford,
A.
Loboda,
Andrew
Albright,
S.
Kang,
S.
Ebbinghaus,
J.
Yearley,
E.
Murphy,
M.
Nebozhyn,
J.
Lunceford,
T.
Mcclanahan,
M.
Ayers,
A.
Daud
(2015)
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Journal of Clinical Oncology, 33
-
S.
Four,
Sarah
Maenhout,
S.
Niclou,
K.
Thielemans,
B.
Neyns,
J.
Aerts
(2016)
Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.
American journal of cancer research, 6 11
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
C.
Robert,
J.
Schachter,
G.
Long,
A.
Arance,
J.
Grob,
L.
Mortier,
A.
Daud,
M.
Carlino,
C.
McNeil,
M.
Lotem,
J.
Larkin,
P.
Lorigan,
B.
Neyns,
C.
Blank,
O.
Hamid,
C.
Mateus,
R.
Shapira-Frommer,
M.
Kosh,
Honghong
Zhou,
N.
Ibrahim,
S.
Ebbinghaus,
A.
Ribas
(2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
The New England journal of medicine, 372 26
-
D.
Pardoll
(2012)
The blockade of immune checkpoints in cancer immunotherapy
Nature Reviews Cancer, 12
-
H.
Hausen
(2000)
Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis
Journal of the National Cancer Institute, 92
-
J.
Taube,
A.
Klein,
J.
Brahmer,
Haiying
Xu,
Xiaoyu
Pan,
J.
Kim,
Lieping
Chen,
D.
Pardoll,
S.
Topalian,
R.
Anders
(2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Clinical Cancer Research, 20
-
日野
亮介
(2010)
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
-
M.
Welters,
T.
Sluis,
H.
Meir,
N.
Loof,
V.
Ham,
Suzanne
Duikeren,
S.
Santegoets,
R.
Arens,
M.
Kam,
A.
Cohen,
M.
Poelgeest,
G.
Kenter,
J.
Kroep,
J.
Burggraaf,
C.
Melief,
S.
Burg
(2016)
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
Science Translational Medicine, 8
-
S.
Piha-Paul,
J.
Bennouna,
Andrew
Albright,
M.
Nebozhyn,
T.
Mcclanahan,
M.
Ayers,
J.
Lunceford,
P.
Ott
(2016)
T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.
Journal of Clinical Oncology, 34
-
S.
Maude,
D.
Teachey,
D.
Porter,
S.
Grupp
(2015)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
Blood, 125 26
-
K.
Tewari,
M.
Sill,
H.
Long,
R.
Penson,
Helen
Huang,
L.
Ramondetta,
L.
Landrum,
A.
Oaknin,
T.
Reid,
M.
Leitao,
Helen
Michael,
B.
Monk
(2014)
Improved survival with bevacizumab in advanced cervical cancer.
The New England journal of medicine, 370 8
-
Wen
Yang,
Yan
Song,
Yun-Long
Lu,
Jun-Zhong
Sun,
Hong-wei
Wang
(2013)
Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia
Immunology, 139
-
O.
Hamid,
C.
Robert,
A.
Daud,
F.
Hodi,
W.
Hwu,
R.
Kefford,
J.
Wolchok,
P.
Hersey,
R.
Joseph,
J.
Weber,
R.
Dronca,
T.
Gangadhar,
A.
Patnaik,
H.
Zarour,
A.
Joshua,
K.
Gergich,
J.
Elassaiss-Schaap,
A.
Algazi,
C.
Mateus,
P.
Boasberg,
P.
Tumeh,
B.
Chmielowski,
S.
Ebbinghaus,
Xiaoyun
Li,
S.
Kang,
A.
Ribas
(2013)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
The New England journal of medicine, 369 2
-
Haidong
Dong,
S.
Strome,
D.
Salomão,
H.
Tamura,
F.
Hirano,
D.
Flies,
P.
Roche,
Jun
Lu,
G.
Zhu,
K.
Tamada,
V.
Lennon,
E.
Celis,
Lieping
Chen
(2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine, 8
-
LarkinJ,
Chiarion-SileniV,
GonzalezR
(2015)
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
N Engl J Med, 373
-
K.
Tewari,
B.
Monk
(2014)
New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy
Clinical Cancer Research, 20
-
W.
Zou,
Lieping
Chen
(2008)
Inhibitory B7-family molecules in the tumour microenvironment
Nature Reviews Immunology, 8